-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c8a40def-dd2e-4d4f-a0da-fcd9af496d89&Preview=1 -
Date
1/3/2008 -
Company Name
Calistoga Pharmaceuticals -
Mailing Address
2101 – 4th Avenue Seattle, WA 98121 -
Company Description
Calistoga Pharmaceuticals, is developing a drug candidate acquired from Icos that has potential to treat various forms of cancer, according to the company.Icos, maker of the impotence drug Cialis, was acquired by its longtime marketing partner, pharmaceutical giant Eli Lilly & Co. (NYSE: LLY), in January, 2007 in a $2.3 billion deal.
-
Website
http://www.calistogapharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$5,200,000 -
Transaction Round
Series A -
Proceeds Purposes
The early infusion of additional resources provides the means to accelerate and expand the Company’s clinical development plan in 2008. -
M&A Terms
-
Venture Investor
Frazier Healthcare Ventures -
Venture Investor
Alta Partners -
Venture Investor
Three Arch Partners -
Venture Investor
Amgen Ventures